Alexion drops kidney disease program for drug that was part of $930M Achillion buyout last year

Achillion Pharmaceuticals, Alexion Pharmaceuticals, ALXN2040, BioPharma, biopharma nl, Boston, C3 glomerulopathy, Daily, danicopan, Massachusetts, SYN, Top Story / July 30, 2020

The company said in its 2Q earnings that it would halt development of ALXN2040 for C3 glomerulopathy, or C3G, citing the drug’s lack of potency. However, it may develop a second, more potent drug from the Achillion acquisition, ALXN2050, in the same disease.